scholarly journals Clinical Significance of High-Mobility Group Box 1 Protein (HMGB1) and Nod-Like Receptor Protein 3 (NLRP3) in Patients with Ulcerative Colitis

2020 ◽  
Vol 26 ◽  
Author(s):  
YanMin Chen ◽  
Dong Wu ◽  
LingJia Sun
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Significance ◽  
High Mobility ◽  
High Mobility Group ◽  
Receptor Protein

The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma

Tumor Biology ◽  
2014 ◽  
Vol 35 (7) ◽  
pp. 6539-6547 ◽  
Author(s):  
Xuhui Zhou ◽  
Bo Yuan ◽  
Wen Yuan ◽  
Ce Wang ◽  
Rui Gao ◽  
...  
Keyword(s):  
Clinical Significance ◽  
High Mobility ◽  
Binding Domain ◽  
High Mobility Group ◽  
Human Osteosarcoma ◽  
Nucleosome Binding

scholarly journals High-Mobility Group Box 1 Protein Signaling in Painful Diabetic Neuropathy

2020 ◽  
Vol 21 (3) ◽  
pp. 881 ◽  
Author(s):  
Vikram Thakur ◽  
Jayanarayanan Sadanandan ◽  
Munmun Chattopadhyay
Keyword(s):  
Diabetic Neuropathy ◽  
Active Form ◽  
High Mobility ◽  
High Mobility Group ◽  
Receptor Protein ◽  
Diabetic Patients ◽  
Hmgb1 Protein ◽  
Painful Neuropathy ◽  
Type 2 Diabetic

Diabetes is a global epidemic and more than 50% diabetic patients are also diagnosed with neuropathy, which greatly affects the quality of life of the patients. Available treatments are not always successful due to the limited efficacy and complications, such as addiction and dependency. Studies have implicated that high mobility group box1 (HMGB1) protein plays a crucial role in neuroinflammation and the development of neuropathic conditions. HMGB1 is a proinflammatory cytokine that can be released from necrotic cells in passive form or in response to inflammatory signals as an active form. HMGB1 is the ligand for the receptor for advanced glycation end products (RAGE), and toll-like receptors, (TLR)-2 and TLR4, which also indirectly activates C-X-C chemokine receptor type 4 (CXCR4). We investigated whether blocking of HMGB1 can reduce pain and inflammation in diabetic neuropathic animals to further understand the role of HMGB1 in diabetic neuropathy. Type 2 diabetic rats and mice were treated with natural inhibitor of HMGB1, glycyrrhizin (GLC) for five days/week for four weeks at a dose of 50 mg/kg per day by intraperitoneal injection. The animals were divided into three categories: naïve control, diabetic alone, diabetic with GLC treatment. All of the behavioral analyses were conducted before and after the treatment. The expression of inflammatory markers and changes in histone acetylation in the peripheral nervous system were measured by immunohistochemistry and Western blot analysis after the completion of the treatment. Our study revealed that TLR4, HMGB1, CXCR4, and Nod-like receptor protein 3 (NLRP3) levels were increased in the spinal and dorsal root ganglia (DRG) neurons of Type 2 diabetic mice and rats with painful neuropathy. GLC treatment inhibited the increases in TLR4, NLRP3, and CXCR4 expressions and improved the mechanical and thermal pain threshold in these animals. Immunohistochemical studies revealed that hyperglycemia mediated inflammation influenced HMGB1 acetylation and its release from the neurons. It also altered histone 3 acetylation in the microglial cells. The inhibition of HMGB1 by GLC prevented the release of HMGB1 as well as H3K9 acetylation. These findings indicate that the interruption of HMGB1 mediated inflammation could ameliorate diabetic neuropathy and might exhibit a unique target for the treatment.

scholarly journals NOD-like receptor protein 3 and high mobility group box-1 are associated with prognosis of patients with congenital heart disease

2019 ◽  
Vol 48 (3) ◽  
pp. 030006051988450
Author(s):  
Jiajie Fan ◽  
Yunxiang Qiu ◽  
Zhijie Zheng ◽  
Luyan Yu ◽  
Shanshan Shi ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Plasma Concentrations ◽  
Prognostic Significance ◽  
High Mobility ◽  
High Mobility Group ◽  
Receptor Protein ◽  
Kaplan Meier ◽  
Oligomerization Domain

Objective To investigate the association between plasma levels of nucleotide-binding oligomerization domain-like (NOD)-like receptor protein 3 (NLRP3) and high mobility group box-1 (HMGB1) and their prognostic significance in neonatal patients with congenital heart disease (CHD). Methods This study enrolled neonatal patients with CHD and collected their demographic and clinical data. Plasma concentrations of NLRP3 and HMGB1 were measured using enzyme-linked immunosorbent assays. Spearman’s analysis was used to determine the correlation between NLRP3 and HMGB1 levels. The association between NLRP3 and HMGB1 levels and 2-year survival and mortality were evaluated using Kaplan–Meier curve and logistic regression analyses. Results A total of 84 neonatal patients with CHD were included in the study. Plasma NLRP3 and HMGB1 levels were significantly higher in deceased patients compared with those that survived. There was a positive correlation between NLRP3 and HMGB1 levels in neonatal patients with CHD. Patients with elevated levels of NLRP3 and HMGB1 showed significantly lower 2-year survival and higher mortality rates compared with those with lower NLRP3 and HMGB1 levels. Conclusion Neonatal patients with CHD and a poor prognosis had higher NLRP3 and HMGB1 levels, which suggests that these might be potential biomarkers of CHD prognosis.

scholarly journals Expression of high mobility group box 1 protein in ulcerative colitis

2014 ◽  
Vol 22 (22) ◽  
pp. 3239
Author(s):  
Zhen Hu ◽  
Xiao-Yun Wang ◽  
Lei Gong ◽  
Gao-Jue Wu ◽  
Xiao-Bin Peng
Keyword(s):  
Ulcerative Colitis ◽  
High Mobility ◽  
High Mobility Group
Sign in / Sign up

Export Citation Format

Share Document